TORONTO, Jan. 29,
2024 /CNW/ - Greenbrook TMS Inc. (NASDAQ: GBNH)
("Greenbrook" or the "Company") today announced that
the Company's Board of Directors has appointed Mr. Peter Willett as the Company's full-time Chief
Financial Officer, effective immediately.
Mr. Willett was appointed Interim Chief Financial Officer of the
Company in October 2023, prior to
which he has been a key player on the Greenbrook finance team over
the past six years, serving as its Senior Vice President of
Finance. Peter brings over 11 years of finance experience,
providing a broad base of experience and specialized knowledge
about the financial and accounting matters that are unique to the
mental health services industry.
Peter has been instrumental in developing and implementing the
financial strategies that have been successful in improving
reporting functions and cost controls for Greenbrook. Peter has a
proven track record of identifying effective processes and
procedures to improve quality, accuracy, and efficiency in
accounting and financial operations.
About Greenbrook TMS
Inc.
Operating through 130 Company-operated treatment centers,
Greenbrook is a leading provider of Transcranial Magnetic
Stimulation ("TMS") therapy and Spravato® (esketamine nasal
spray), FDA-cleared, non-invasive therapies for the treatment of
Major Depressive Disorder ("MDD") and other mental health
disorders, in the United States.
TMS therapy provides local electromagnetic stimulation to specific
brain regions known to be directly associated with mood regulation.
Spravato® is offered to treat adults with treatment-resistant
depression and depressive symptoms in adults with MDD with suicidal
thoughts or actions. Greenbrook has provided more than 1.3 million
treatments to over 40,000 patients struggling with depression.
View original
content:https://www.prnewswire.com/news-releases/greenbrook-appoints-peter-willett-as-chief-financial-officer-302047168.html
SOURCE Greenbrook TMS Inc.